NK Cell STAT3 and Virus-induced IL-6 Disease
NK 细胞 STAT3 和病毒诱导的 IL-6 疾病
基本信息
- 批准号:9352931
- 负责人:
- 金额:$ 59.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-23 至 2019-08-31
- 项目状态:已结题
- 来源:
- 关键词:Anti-Retroviral AgentsAntiviral AgentsAutoimmune ProcessCell physiologyCellsChronic DiseaseCytokine ActivationCytomegalovirus InfectionsDiseaseHIVHealthHumanImmuneImmune responseImmune systemInfectionInflammatoryInterleukin-6LaboratoriesLicensingLiverMalignant NeoplasmsMediatingModelingMono-SMorphologyMurid herpesvirus 1Natural Killer CellsPathologyPathway interactionsPlayProductionRheumatoid ArthritisRoleShapesSignal TransductionSourceSpleenStat3 proteinSyndromeTestingTissuesVirusVirus DiseasesVirus ReplicationWorkbasecell typecellular targetingclinically relevantconditioningcytokineinfancynovelnovel therapeuticsprotective effectresponse
项目摘要
DESCRIPTION (provided by applicant): Both innate cytokines and immune cells contribute to defense against viral infections. Virus is a critical part of pathology during infection. Frequentl, however, elicited immune responses rather than the agent itself cause the detrimental consequences of infection. The cytokine IL-6 is one factor that can play a role in chronic diseases such as rheumatoid arthritis (RA) and may be part of the immune reactivation inflammatory syndrome (IRIS) following successful anti-retroviral therapy (ART) in HIV-infected humans, but the mechanisms by which it leads to disease are not known. Natural killer (NK) cells of the innate immune system play important roles in direct antiviral defense and in shaping the magnitudes of other immune responses to protect against immune-mediated pathology. Different mechanisms inducing and regulating NK cell responses, as well as pathways by which NK cell-mediated effects are delivered, have been elucidated. Nevertheless, nothing is known about how NK cells respond to or regulate IL-6 production. During studies of the expression and function of the signal transducer and activator of transcription 3 (STAT3) in NK cells, this laboratory has discovered a novel, STAT3-dependent role for NK cells in protecting against IL-6-dependent disease during murine cytomegalovirus (MCMV) infection. Based on existing information and our new preliminary studies, our hypothesis is that a cascade response leading to IL-6-mediated disease is regulated (a) by cytokine induction and activation of STAT3 in NK cells, (b) to limit IL-6 production by particular cell types, (c) to in turn protect against IL-6-mediated disease. The studies planned here will test this hypothesis in three specific aims defining: (1) the NK cell functions regulated by STAT3, (2) the pathway(s) by which NK cells regulate IL-6 production, and (3) the mechanism(s) used by IL-6 to induce disease. The studies will characterize conditioning of NK cell responses to a variety of induced cytokines, and changing IL-6 effects on immune and non-immune cell subsets, in the spleen and liver as infection progresses. The work has broad clinical relevance. It promises to greatly advance understanding of the ways by which IL-6 can cause disease and to define yet another important role played by NK cells in protecting against detrimental effects during viral infections.
描述(由申请人提供):先天细胞因子和免疫细胞都有助于防御病毒感染,但病毒通常会引起免疫反应,而不是细胞因子本身引起感染。 -6 是在类风湿性关节炎 (RA) 等慢性疾病中发挥作用的因素之一,并且可能是成功抗逆转录病毒治疗 (ART) 后免疫再激活炎症综合征 (IRIS) 的一部分。感染艾滋病毒的人类,但其导致疾病的机制尚不清楚,先天免疫系统的自然杀伤(NK)细胞在直接抗病毒防御和塑造其他免疫反应的强度方面发挥着重要作用,以防止免疫系统的破坏。然而,在研究过程中,关于 NK 细胞如何响应或调节 IL-6 的产生尚不清楚。表达式和函数的该实验室基于 NK 细胞中信号转导器和转录激活剂 3 (STAT3) 的功能,在现有的基础上,发现了 NK 细胞在预防小鼠巨细胞病毒 (MCMV) 感染期间预防 IL-6 依赖性疾病方面的一种新的、依赖于 STAT3 的作用。根据我们的信息和新的初步研究,我们的假设是,导致 IL-6 介导的疾病的级联反应受到 (a) NK 细胞中细胞因子诱导和 STAT3 激活的调节,(b) 限制 IL-6 (c) 进而预防 IL-6 介导的疾病。这里计划的研究将在三个具体目标中检验这一假设:(1) STAT3 调节的 NK 细胞功能,(2) STAT3 调节的 NK 细胞功能。 NK 细胞调节 IL-6 产生的途径,以及 (3) IL-6 诱导疾病的机制。这些研究将表征 NK 细胞对各种诱导细胞因子的反应的调节,以及变化。 IL-6 对免疫和非免疫的影响随着感染的进展,这项工作有望极大地促进对 IL-6 引起疾病的方式的理解,并确定 NK 细胞在预防感染方面发挥的另一个重要作用。病毒感染期间的不良影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTINE A. BIRON其他文献
CHRISTINE A. BIRON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTINE A. BIRON', 18)}}的其他基金
Type 1 IFN Function and Signaling in Immunity to Viruses
1 型干扰素在病毒免疫中的功能和信号传导
- 批准号:
7682782 - 财政年份:2008
- 资助金额:
$ 59.23万 - 项目类别:
EVENTS REGULATING THE BALANCE BETWEEN RESISTANCE & INFECTION
调节阻力平衡的事件
- 批准号:
7170316 - 财政年份:2005
- 资助金额:
$ 59.23万 - 项目类别:
EVENTS REGULATING THE BALANCE BETWEEN RESISTANCE & INFECTION
调节阻力平衡的事件
- 批准号:
7011753 - 财政年份:2004
- 资助金额:
$ 59.23万 - 项目类别:
Type 1 IFN Function and Signaling in Immunity to Viruses
1 型干扰素在病毒免疫中的功能和信号传导
- 批准号:
6671292 - 财政年份:2003
- 资助金额:
$ 59.23万 - 项目类别:
Type 1 IFN Function and Signaling in Immunity to Viruses
1 型干扰素在病毒免疫中的功能和信号传导
- 批准号:
8309406 - 财政年份:2003
- 资助金额:
$ 59.23万 - 项目类别:
Type 1 IFN Function and Signaling in Immunity to Viruses
1 型干扰素在病毒免疫中的功能和信号传导
- 批准号:
6758522 - 财政年份:2003
- 资助金额:
$ 59.23万 - 项目类别:
Type 1 IFN Function and Signaling in Immunity to Viruses
1 型干扰素在病毒免疫中的功能和信号传导
- 批准号:
7148056 - 财政年份:2003
- 资助金额:
$ 59.23万 - 项目类别:
Type 1 IFN Function and Signaling in Immunity to Viruses
1 型干扰素在病毒免疫中的功能和信号传导
- 批准号:
8112698 - 财政年份:2003
- 资助金额:
$ 59.23万 - 项目类别:
Type 1 IFN Function and Signaling in Immunity to Viruses
1 型干扰素在病毒免疫中的功能和信号传导
- 批准号:
7787580 - 财政年份:2003
- 资助金额:
$ 59.23万 - 项目类别:
Type 1 IFN Function and Signaling in Immunity to Viruses
1 型干扰素在病毒免疫中的功能和信号传导
- 批准号:
6824915 - 财政年份:2003
- 资助金额:
$ 59.23万 - 项目类别:
相似国自然基金
基于激发植物免疫为导向的嘧啶酮类高效抗病毒剂设计合成及作用机制研究
- 批准号:21807037
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
云南地方晾晒烟中的内源性抗烟草花叶病毒活性成分研究
- 批准号:31860100
- 批准年份:2018
- 资助金额:41.0 万元
- 项目类别:地区科学基金项目
基于kealiinine类海洋生物碱的新型抗病毒剂的设计合成、构效关系及作用机制研究
- 批准号:21772145
- 批准年份:2017
- 资助金额:64.0 万元
- 项目类别:面上项目
两种植物中抗烟草花叶病毒先导化合物的结构优化、构效关系及作用机制研究
- 批准号:31760089
- 批准年份:2017
- 资助金额:38.0 万元
- 项目类别:地区科学基金项目
生态农药的分子设计与作用机制
- 批准号:21732002
- 批准年份:2017
- 资助金额:300.0 万元
- 项目类别:重点项目
相似海外基金
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
- 批准号:
9922602 - 财政年份:2020
- 资助金额:
$ 59.23万 - 项目类别:
Engineering an HIV-resistant immune system for HIV cure
设计抗艾滋病毒免疫系统以治愈艾滋病毒
- 批准号:
9063293 - 财政年份:2016
- 资助金额:
$ 59.23万 - 项目类别:
Engineering an HIV-resistant immune system for HIV cure
设计抗艾滋病毒免疫系统以治愈艾滋病毒
- 批准号:
9198935 - 财政年份:2016
- 资助金额:
$ 59.23万 - 项目类别:
An Antiviral to Treat Progressive Multifocal Leukoencephalopathy_(PML)
一种治疗进行性多灶性白质脑病 (PML) 的抗病毒药物
- 批准号:
8906181 - 财政年份:2015
- 资助金额:
$ 59.23万 - 项目类别:
HLA restriction and TCR affinity in HIV
HIV 中的 HLA 限制和 TCR 亲和力
- 批准号:
8298440 - 财政年份:2011
- 资助金额:
$ 59.23万 - 项目类别: